## Luca G G Guidotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2493005/publications.pdf

Version: 2024-02-01

109 papers 14,958 citations

63 h-index 30087 103 g-index

112 all docs

112 docs citations

112 times ranked

12151 citing authors

#	Article	IF	CITATIONS
1	Immunobiology and pathogenesis of hepatitis B virus infection. Nature Reviews Immunology, 2022, 22, 19-32.	22.7	199
2	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Molecular Therapy, 2022, 30, 311-326.	8.2	54
3	Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Science Immunology, 2022, $7$ , .	11.9	61
4	Group 1 ILCs regulate T cell–mediated liver immunopathology by controlling local IL-2 availability. Science Immunology, 2022, 7, eabi6112.	11.9	18
5	Lowâ€dose aspirin reduces the risk of HBVâ€associated HCC even when administered shortâ€ŧerm: Too good to be true?. Hepatology, 2022, 76, 300-302.	7.3	2
6	Developing a cure for chronic hepatitis B requires a fresh approach. Nature, 2022, 603, S49-S49.	27.8	3
7	Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets. Science Signaling, 2022, 15, eabb0384.	3.6	2
8	Immunological insights in the treatment of chronic hepatitis B. Current Opinion in Immunology, 2022, 77, 102207.	5 <b>.</b> 5	5
9	Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators. Bioorganic and Medicinal Chemistry Letters, 2022, 73, 128904.	2.2	2
10	Identification of a Kupffer cell subset capable of reverting the Tâcell dysfunction induced by hepatocellular priming. Immunity, 2021, 54, 2089-2100.e8.	14.3	73
11	Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Science Immunology, 2021, , eabl9929.	11.9	3
12	Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. Journal of Experimental Medicine, 2020, 217, .	8.5	31
13	Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?. Gastroenterology, 2020, 159, 1988-1990.	1.3	1
14	Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature, 2019, 574, 200-205.	27.8	135
15	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
16	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	8.1	342
17	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. Journal of Hepatology, 2017, 67, 543-548.	3.7	48
18	Pathogenâ€specific Bâ€cell receptors drive chronic lymphocytic leukemia by lightâ€chainâ€dependent crossâ€reaction with autoantigens. EMBO Molecular Medicine, 2017, 9, 1482-1490.	6.9	15

#	Article	IF	CITATIONS
19	Microcirculation in the murine liver: a computational fluid dynamic model based on 3D reconstruction from in vivo microscopy. Journal of Biomechanics, 2017, 63, 125-134.	2.1	12
20	$\langle scp \rangle IFN \langle  scp \rangle \hat{l} \pm gene/cell$ therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. EMBO Molecular Medicine, 2016, 8, 155-170.	6.9	29
21	Hepatitis B Virus Immunopathogenesis. Molecular and Translational Medicine, 2016, , 79-93.	0.4	0
22	Inflammatory monocytes hinder antiviral B cell responses. Science Immunology, 2016, 1, .	11.9	93
23	Protective and Pathogenic T Cell Responses to Virus Infections. , 2016, , 318-323.		1
24	Eukaryotic translation initiation factor 6 is a novel regulator of reactive oxygen species-dependent megakaryocyte maturation. Journal of Thrombosis and Haemostasis, 2015, 13, 2108-2118.	3.8	13
25	Host–virus interactions in hepatitis B virus infection. Current Opinion in Immunology, 2015, 36, 61-66.	5.5	133
26	Immunosurveillance of the Liver by Intravascular Effector CD8 + T Cells. Cell, 2015, 161, 486-500.	28.9	271
27	Mouse Models of Hepatitis B Virus Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021477.	6.2	23
28	Editorial overview: Viral pathogenesis. Current Opinion in Virology, 2015, 11, v-vii.	5.4	2
29	The COP9 signalosome is a repressor of replicative stress responses and polyploidization in the regenerating liver. Hepatology, 2014, 59, 2331-2343.	<b>7.</b> 3	6
30	In Vivo Flow Mapping in Complex Vessel Networks by Single Image Correlation. Scientific Reports, 2014, 4, 7341.	3.3	21
31	Animal Models of Hepatitis B and C. , 2014, , 44-49.		0
32	Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1135-1138.	3.7	82
33	TIE2-expressing monocytes regulate revascularisation of the ischaemic limb. Lancet, The, 2013, 381, S78.	13.7	0
34	Bisphosphonates Target B Cells to Enhance Humoral Immune Responses. Cell Reports, 2013, 5, 323-330.	6.4	39
35	Effector CD8 T cell trafficking within the liver. Molecular Immunology, 2013, 55, 94-99.	2.2	29
36	Nkx2-5+Islet1+ Mesenchymal Precursors Generate Distinct Spleen Stromal Cell Subsets and Participate in Restoring Stromal Network Integrity. Immunity, 2013, 38, 782-791.	14.3	82

#	Article	IF	CITATIONS
37	TIE2â€expressing monocytes/macrophages regulate revascularization of the ischemic limb. EMBO Molecular Medicine, 2013, 5, 858-869.	6.9	83
38	Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2165-72.	7.1	267
39	Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help. Journal of Immunology, 2012, 188, 3217-3222.	0.8	90
40	Kupffer Cells Hasten Resolution of Liver Immunopathology in Mouse Models of Viral Hepatitis. PLoS Pathogens, 2011, 7, e1002061.	4.7	96
41	Role of CCL2/MCP-1 in Islet Transplantation. Cell Transplantation, 2010, 19, 1031-1046.	2.5	69
42	Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature, $2010, 465, 1079-1083$ .	27.8	309
43	Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection. PLoS Pathogens, 2010, 6, e1001227.	4.7	228
44	Modulation of Early Inflammatory Reactions to Promote Engraftment and Function of Transplanted Pancreatic Islets in Autoimmune Diabetes. Advances in Experimental Medicine and Biology, 2010, 654, 725-747.	1.6	25
45	On the role of platelets in the pathogenesis of viral hepatitis. Journal of Hepatology, 2009, 51, 599-600.	3.7	16
46	Bone marrow as an alternative site for islet transplantation. Blood, 2009, 114, 4566-4574.	1.4	72
47	Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. Cancer Cell, 2008, 14, 299-311.	16.8	267
48	Platelets prevent IFN- $\hat{l}\pm/\hat{l}^2$ -induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 629-634.	7.1	119
49	Antiplatelet Drug Therapy Moderates Immune-Mediated Liver Disease and Inhibits Viral Clearance in Mice Infected with a Replication-Deficient Adenovirus. Vaccine Journal, 2007, 14, 1532-1535.	3.1	56
50	Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. Journal of Leukocyte Biology, 2007, 81, 100-107.	3.3	120
51	In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood, 2007, 109, 2797-2805.	1.4	168
52	HBV pathogenesis in animal models: Recent advances on the role of platelets. Journal of Hepatology, 2007, 46, 719-726.	3.7	84
53	IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 23-61.	22.4	669
54	Reduced severity of liver ischemia/reperfusion injury following hepatic resection in humans is associated with enhanced intrahepatic expression of Th2 cytokines. Hepatology Research, 2006, 36, 20-26.	3.4	15

#	Article	IF	Citations
55	Defective Th1 Cytokine Gene Transcription in CD4+ and CD8+ T Cells from Wiskott-Aldrich Syndrome Patients. Journal of Immunology, 2006, 177, 7451-7461.	0.8	103
56	Pathogenetic and antiviral immune responses against hepatitis B virus. Future Virology, 2006, 1, 189-196.	1.8	17
57	Naive HIV/HCV-Coinfected Patients Have Higher Intrahepatic Pro-Inflammatory Cytokines than Coinfected Patients Treated with Antiretroviral Therapy. Antiviral Therapy, 2006, 11, 385-389.	1.0	13
58	Pathogenesis of Hepatitis B Virus inTransgenic Mice., 2005, 25, 25-32.		1
59	Platelets mediate cytotoxic T lymphocyte–induced liver damage. Nature Medicine, 2005, 11, 1167-1169.	30.7	311
60	Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins. Journal of Virology, 2005, 79, 3016-3027.	3.4	194
61	Platelets Mediate Cytotoxic T Lymphocyte-Induced Liver Damage Blood, 2005, 106, 651-651.	1.4	0
62	A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14913-14918.	7.1	219
63	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. Journal of Clinical Investigation, 2004, 113, 1158-1167.	8.2	106
64	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. Journal of Clinical Investigation, 2004, 113, 1158-1167.	8.2	63
65	Searching for Interferon-Induced Genes That Inhibit Hepatitis B Virus Replication in Transgenic Mouse Hepatocytes. Journal of Virology, 2003, 77, 1227-1236.	3.4	108
66	Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13717-13722.	7.1	110
67	Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11181-11186.	7.1	183
68	Interleukin-18 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. Journal of Virology, 2002, 76, 10702-10707.	3.4	166
69	Activated Intrahepatic Antigen-Presenting Cells Inhibit Hepatitis B Virus Replication in the Liver of Transgenic Mice. Journal of Immunology, 2002, 169, 5188-5195.	0.8	109
70	Interferon-Regulated Pathways That Control Hepatitis B Virus Replication in Transgenic Mice. Journal of Virology, 2002, 76, 2617-2621.	3.4	112
71	The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine, 2002, 20, A80-A82.	3.8	47
72	Noncytolytic Control of Viral Infections by the Innate and Adaptive ImmuneResponse. Annual Review of Immunology, 2001, 19, 65-91.	21.8	896

#	Article	IF	CITATIONS
73	Characterization of Nuclear RNases That Cleave Hepatitis B Virus RNA near the La Protein Binding Site. Journal of Virology, 2001, 75, 6874-6883.	3.4	53
74	Blocking Chemokine Responsive to γ–2/Interferon (IFN)-γ Inducible Protein and Monokine Induced by IFN-γ Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 2001, 194, 1755-1766.	8.5	225
75	Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice. Journal of Immunology, 2001, 166, 1389-1397.	0.8	73
76	Nuclear Covalently Closed Circular Viral Genomic DNA in the Liver of Hepatocyte Nuclear Factor $1\hat{l}\pm$ -Null Hepatitis B Virus Transgenic Mice. Journal of Virology, 2001, 75, 2900-2911.	3.4	103
77	Cutting Edge: Inhibition of Hepatitis B Virus Replication by Activated NK T Cells Does Not Require Inflammatory Cell Recruitment to the Liver. Journal of Immunology, 2001, 167, 6701-6705.	0.8	102
78	Cytokine-Mediated Control of Viral Infections. Virology, 2000, 273, 221-227.	2.4	123
79	Inhibition of Hepatitis B Virus Replication during Schistosoma mansoni Infection in Transgenic Mice. Journal of Experimental Medicine, 2000, 192, 289-294.	8.5	39
80	Host–Virus Interactions during Malaria Infection in Hepatitis B Virus Transgenic Mice. Journal of Experimental Medicine, 2000, 192, 529-536.	8.5	61
81	Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo. Journal of Experimental Medicine, 2000, 192, 921-930.	8.5	560
82	Nitric Oxide Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. Journal of Experimental Medicine, 2000, 191, 1247-1252.	8.5	117
83	Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines. Journal of Virology, 2000, 74, 2255-2264.	3.4	238
84	Intrahepatic Induction of Alpha/Beta Interferon Eliminates Viral RNA-Containing Capsids in Hepatitis B Virus Transgenic Mice. Journal of Virology, 2000, 74, 4165-4173.	3.4	226
85	La Autoantigen Specifically Recognizes a Predicted Stem-Loop in Hepatitis B Virus RNA. Journal of Virology, 1999, 73, 5767-5776.	3.4	79
86	Noncytopathic Clearance of Lymphocytic Choriomeningitis Virus from the Hepatocyte. Journal of Experimental Medicine, 1999, 189, 1555-1564.	8.5	141
87	Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection. Science, 1999, 284, 825-829.	12.6	1,144
88	Cytokine-induced viral purging â€" role in viral pathogenesis. Current Opinion in Microbiology, 1999, 2, 388-391.	5.1	73
89	Hepatitis B Virus RNA-Binding Proteins Associated with Cytokine-Induced Clearance of Viral RNA from the Liver of Transgenic Mice. Journal of Virology, 1999, 73, 474-481.	3.4	91
90	In Vivo Regulation of Hepatitis B Virus Replication by Peroxisome Proliferators. Journal of Virology, 1999, 73, 10377-10386.	3.4	51

#	Article	IF	Citations
91	Thymic Tolerance to Only One Viral Protein Reduces Lymphocytic Choriomeningitis Virus-Induced Immunopathology and Increases Survival in Perforin-Deficient Mice. Journal of Virology, 1999, 73, 5918-5925.	3.4	16
92	Mouse genetics at work: A new model of chronic hepadnavirus infection. Hepatology, 1998, 28, 268-269.	7.3	2
93	The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunologic Research, 1998, 18, 79-92.	2.9	115
94	Immune Pathogenesis of Hepatocellular Carcinoma. Journal of Experimental Medicine, 1998, 188, 341-350.	8.5	354
95	Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice. Journal of Virology, 1998, 72, 2630-2637.	3.4	138
96	Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology, 1997, 25, 719-727.	7.3	133
97	Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes. Immunity, 1996, 4, 25-36.	14.3	1,065
98	Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4589-4594.	7.1	196
99	Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant hepatitis. Hepatology, 1996, 24, 649-656.	7.3	32
100	To kill or to cure: options in host defense against viral infection. Current Opinion in Immunology, 1996, 8, 478-483.	5.5	257
101	The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. Journal of Virology, 1996, 70, 7056-7061.	3.4	113
102	Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 12398-12402.	7.1	123
103	Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3764-3768.	7.1	416
104	Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. Journal of Virology, 1994, 68, 1265-1270.	3.4	133
105	Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. Journal of Virology, 1994, 68, 5469-5475.	3.4	109
106	Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis Journal of Experimental Medicine, 1993, 178, 1541-1554.	8.5	470
107	Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. Journal of Virology, 1993, 67, 7444-7449.	3.4	81
108	High-performance liquid chromatographic determination of d-amino acid oxidase activity. Biomedical Applications, 1991, 566, 377-382.	1.7	7

 #	Article	IF	CITATIONS
109	A Derivatization Procedure Suitable for HPLC Analysis of Clenbuterol. Journal of Chromatographic Science, 1991, 29, 190-193.	1.4	14